Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,187,343
  • Shares Outstanding, K 57,056
  • Annual Sales, $ 1,891 M
  • Annual Income, $ 447,100 K
  • 60-Month Beta 1.23
  • Price/Sales 3.88
  • Price/Cash Flow 7.67
  • Price/Book 2.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 2.83
  • Number of Estimates 7
  • High Estimate 3.14
  • Low Estimate 2.63
  • Prior Year 2.63
  • Growth Rate Est. (year over year) +7.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
125.42 +3.48%
on 04/22/19
144.94 -10.46%
on 04/08/19
-6.82 (-4.99%)
since 03/22/19
3-Month
119.54 +8.57%
on 02/12/19
144.94 -10.46%
on 04/08/19
+1.77 (+1.38%)
since 01/23/19
52-Week
113.52 +14.32%
on 12/24/18
184.00 -29.47%
on 06/20/18
-25.86 (-16.62%)
since 04/23/18

Most Recent Stories

More News
Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 first quarter financial results on Tuesday, May 7, 2019, after the close of the financial markets. Company management...

JAZZ : 129.78 (+3.02%)
JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ : 129.78 (+3.02%)
ZTS : 101.97 (+1.85%)
3 Reasons Why Jazz (JAZZ) Is a Great Growth Stock

Jazz (JAZZ) could produce exceptional returns because of its solid growth attributes.

JAZZ : 129.78 (+3.02%)
Report: Developing Opportunities within Noble, Harris, Jazz Pharmaceuticals, Teradata, Abeona Therapeutics, and Otonomy -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Noble Corporation (NYSE:NE),...

TDC : 45.61 (+1.11%)
JAZZ : 129.78 (+3.02%)
ABEO : 8.24 (+3.13%)
NE : 3.08 (+3.70%)
HRS : 167.52 (+1.61%)
OTIC : 2.67 (+1.52%)
Concert Pharma Initiates Early-Stage Schizophrenia Study

Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.

CELG : 93.67 (+0.27%)
CNCE : 9.65 (+2.01%)
JAZZ : 129.78 (+3.02%)
INCY : 75.41 (+2.38%)
Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study

Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.

AVDL : 1.11 (-7.50%)
JAZZ : 129.78 (+3.02%)
NVS : 75.90 (+0.66%)
TEVA : 14.91 (+1.43%)
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

JZP-258 achieves primary and key secondary endpoints demonstrating highly statistically significant differences in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo...

JAZZ : 129.78 (+3.02%)
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the global, double-blind, placebo-controlled, randomized-withdrawal, multicenter Phase 3 study evaluating the efficacy...

JAZZ : 129.78 (+3.02%)
Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi(TM) (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy...

JAZZ : 129.78 (+3.02%)
Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi(TM) (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Sunosi(TM) (solriamfetol) to improve wakefulness in adult patients with excessive daytime...

JAZZ : 129.78 (+3.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade JAZZ with:

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Key Turning Points

2nd Resistance Point 133.19
1st Resistance Point 131.48
Last Price 129.78
1st Support Level 127.33
2nd Support Level 124.89

See More

52-Week High 184.00
Fibonacci 61.8% 157.08
Fibonacci 50% 148.76
Fibonacci 38.2% 140.44
Last Price 129.78
52-Week Low 113.52

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar